We invest in early-stage innovative life science companies of strategic interest.
At Sanofi-Genzyme BioVentures we are different from traditional venture capital firms: we only invest in early-stage life science companies developing innovative products or technologies of interest to Sanofi. In 2017, we expanded our mandate to seed, lead and co-lead investments in order to maximize our impact to Sanofi. We also back our financial support with world class technical and strategic guidance through access to the Sanofi teams.
"With this new allocation, we will have the ability to lead financings in order to be more impactful and we will follow a more focused investment strategy of making meaningful investments in bio-therapeutic and digital health opportunities that create strategic optionality for Sanofi,"
Vice-President and Managing Director